Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark J Wall

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
Bioorganic & Medicinal Chemistry Letters|October 22, 2013
Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitorsCarl R Illig, Carl L Manthey, Sanath K Meegalla, et al.
Bioorganic & Medicinal Chemistry Letters|February 22, 2008
Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitorsMark J Wall, Jinsheng Chen, Sanath Meegalla, et al.
Nature Communications|July 19, 2022
Selective activation of Gαob by an adenosine A<sub>1</sub> receptor agonist elicits analgesia without cardiorespiratory depressionMark J Wall, Emily Hill, Robert Huckstepp, et al.
Molecular Cancer Therapeutics|November 6, 2009
JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemiaCarl L Manthey, Dana L Johnson, Carl R Illig, et al.
Nature Medicine|February 10, 2025
Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer's diseaseTohidul Islam, Emily Hill, Eric E Abrahamson, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
Bioorganic & Medicinal Chemistry Letters|October 22, 2013
Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitorsCarl R Illig, Carl L Manthey, Sanath K Meegalla, et al.
Bioorganic & Medicinal Chemistry Letters|February 22, 2008
Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitorsMark J Wall, Jinsheng Chen, Sanath Meegalla, et al.
Nature Communications|July 19, 2022
Selective activation of Gαob by an adenosine A<sub>1</sub> receptor agonist elicits analgesia without cardiorespiratory depressionMark J Wall, Emily Hill, Robert Huckstepp, et al.
Molecular Cancer Therapeutics|November 6, 2009
JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemiaCarl L Manthey, Dana L Johnson, Carl R Illig, et al.
Nature Medicine|February 10, 2025
Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer's diseaseTohidul Islam, Emily Hill, Eric E Abrahamson, et al.
Pageof 8